Prostate Cancer News and Research

Latest Prostate Cancer News and Research

First Edition: January 6, 2012

In today's news, reports from the campaign trail and details about how nine states have asked the federal government for more funding to make sure their high-risk pools don't run out of cash before 2014.

6 Jan 2012

Proton therapy safe and effective for men with prostate cancer

Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies published in the January issue of the International Journal of Radiation Oncology-Biology-Physics (Red Journal), the American Society for Radiation Oncology's (ASTRO) official scientific journal.

6 Jan 2012

LCA calls for more aggressive integration of imaging advances and biomedical research

As the War on Cancer enters its fifth decade and the number of people being diagnosed with cancer continues to rise, Lung Cancer Alliance (LCA) called for more aggressive integration of advanced imaging technology and biomedical research to improve prevention, earlier detection and treatment of cancer.

6 Jan 2012

Arrowhead receives FDA IND approval for Adipotide obesity drug

Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.

5 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

Four or more coffees reduce risk of womb cancer

According to a new study drinking four or more cups of coffee a day may reduce risk of developing endometrial cancer or womb cancer by almost 25 per cent.

1 Jan 2012

Similar sounding drug names should come with warnings

There have been mix ups and medication errors with similar sounding names of drugs - eye drops called Durezol and salicylic acid-containing wart remedy Duresal for example.

1 Jan 2012

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

30 Dec 2011

New initiative to detect cancers in earliest stages inside cells

A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers.

29 Dec 2011

Research roundup: Unraveling why elderly men are tested for prostate cancer; Difficulty paying medical bills

Medical Center Characteristics Associated With PSA Screenings In Elderly Veterans With Limited Life Expectancy -- Medical guidelines recommend against prostate-specific antigen (PSA) screenings for prostate cancer in men with limited life expectancy, but studies have shown that many elderly men still get the test.

23 Dec 2011

UC San Diego surgeon removes diseased gallbladder through belly button

On Tuesday, December 20th, Santiago Horgan, MD, chief of minimally invasive surgery at UC San Diego Health System was the first surgeon in the United States to remove a diseased gallbladder through a patient's belly button with the aid of a new FDA-approved da Vinci Si Surgical System.

23 Dec 2011

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

Soybean compounds can increase effectiveness of radiation treatment for lung cancer

A Wayne State University researcher has shown that compounds found in soybeans can make radiation treatment of lung cancer tumors more effective while helping to preserve normal tissue.

19 Dec 2011

Nitroglycerin can boost body's natural immune response to cancer

Researchers at Queen's University have identified a new mechanism that could potentially explain why the body's immune system sometimes fails to eliminate cancer. The new findings shed light on the possible cause of immune resistance in cancer cells, and indicate that nitroglycerin, a relatively safe and low-cost drug used for more than a century to treat angina, may be effective for managing certain cancers.

15 Dec 2011

Cancer screening: Is it necessary in the elderly?

There is a long ongoing debate on whether the elderly need to be routinely screened for cancers. A new survey shows that the majority of nearly 19 million Americans over age 75 dutifully get screened for breast, prostate, and colon cancers each year.

14 Dec 2011

Study: High cancer screening rates seen among elderly adults

Adults older than 75 years continue to have regular screenings for colorectal, breast, cervical, and prostate cancer despite guidelines that recommend against such routine screenings in this population, according to a study by Keith M. Bellizzi, MD, MPH, from the University of Connecticut, Storrs, and colleagues.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Higher individual doses of radiotherapy safe for men with prostate cancer

Less overall radiotherapy, delivered in fewer but higher doses, is as safe as standard, lower doses for treating prostate cancer, according to new research* published in the Lancet Oncology.

13 Dec 2011

No change toward more aggressive biopsy follow-up of PSA tests, finds study

After the US Prostate Cancer Prevention Trial found cancer in many men with low levels of prostate specific antigen (PSA), many debated which PSA level should lead to a biopsy recommendation. The US Preventive Screening Task Force (USPSTF) recently concluded, amid considerable controversy, that the evidence does not support recommending PSA screening for men under 75 years old at all, because the risks outweigh the benefits.

13 Dec 2011